Metalloproteinases and their inhibitors as therapeutic targets for multiple sclerosis : current evidence and future perspectives

php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Metalloproteinases In Medicine 2017:4 1–13 Metalloproteinases In Medicine Dovepress

[1]  B. Engelhardt,et al.  Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis , 2016, European journal of immunology.

[2]  B. Khatri.  Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence , 2016, Therapeutic advances in neurological disorders.

[3]  P. Vitaglione,et al.  Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study , 2016, Experimental biology and medicine.

[4]  M. Noakes,et al.  Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease. , 2015, Heart, lung & circulation.

[5]  G. Di Bari,et al.  Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures , 2015, PloS one.

[6]  G. Murphy,et al.  Extracellular regulation of metalloproteinases. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[7]  P. Calder.  Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. , 2015, Biochimica et biophysica acta.

[8]  P. Riccio,et al.  Nutrition Facts in Multiple Sclerosis , 2015, ASN neuro.

[9]  G. Fields.  New strategies for targeting matrix metalloproteinases , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[10]  H. Lassmann.  Multiple sclerosis: Lessons from molecular neuropathology , 2014, Experimental Neurology.

[11]  P. Calder,et al.  Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. , 2014, Pharmacology & therapeutics.

[12]  H. Hsieh,et al.  Role of Redox Signaling in Neuroinflammation and Neurodegenerative Diseases , 2013, BioMed research international.

[13]  B. N. Tomlinson,et al.  Selective Inhibition of Matrix Metalloproteinase-9 Attenuates Secondary Damage Resulting from Severe Traumatic Brain Injury , 2013, PloS one.

[14]  G. Di Bari,et al.  Impact of manganese neurotoxicity on MMP-9 production and superoxide dismutase activity in rat primary astrocytes. Effect of resveratrol and therapeutical implications for the treatment of CNS diseases. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  A. Zarzuelo,et al.  Minocycline: far beyond an antibiotic , 2013, British journal of pharmacology.

[16]  Jiankun Cui,et al.  Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia , 2012, Molecular Neurodegeneration.

[17]  Adela C. Bonoiu,et al.  Suppression of MMP-9 Expression in Brain Microvascular Endothelial Cells (BMVEC) Using a Gold Nanorod (GNR)-siRNA Nanoplex , 2012, Immunological investigations.

[18]  R. Pi,et al.  The prospects of minocycline in multiple sclerosis , 2011, Journal of Neuroimmunology.

[19]  H. D. de Vries,et al.  Radical changes in multiple sclerosis pathogenesis. , 2011, Biochimica et biophysica acta.

[20]  T. Latronico,et al.  Structure-Dependent Inhibition of Gelatinases by Dietary Antioxidants in Rat Astrocytes and Sera of Multiple Sclerosis Patients , 2011, Neurochemical Research.

[21]  N. Thomas,et al.  Metalloproteinase Inhibitors: Status and Scope from Marine Organisms , 2010, Biochemistry research international.

[22]  H. Hsieh,et al.  Transforming growth factor-β1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-κB pathways , 2010, Journal of Neuroinflammation.

[23]  F. Zipp,et al.  Neuronal injury in chronic CNS inflammation. , 2010, Best practice & research. Clinical anaesthesiology.

[24]  M. Martí,et al.  Inhibitory effect of quercetin on matrix metalloproteinase 9 activity molecular mechanism and structure-activity relationship of the flavonoid-enzyme interaction. , 2010, European journal of pharmacology.

[25]  H. Perron,et al.  The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation , 2010, Clinical reviews in allergy & immunology.

[26]  S. Baranzini,et al.  Multiple sclerosis genetics—is the glass half full, or half empty? , 2010, Nature Reviews Neurology.

[27]  Hong Ding,et al.  MMP-9 gene silencing by a quantum dot–siRNA nanoplex delivery to maintain the integrity of the blood brain barrier , 2009, Brain Research.

[28]  T. Olsson,et al.  The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment‐sensitive biomarkers , 2009, European journal of neurology.

[29]  C. A. Foster,et al.  FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood‐Brain‐Barrier Damage , 2009, Brain pathology.

[30]  Chen Zhang,et al.  Matrix Metalloproteinase Inhibitors (MMPIs) from Marine Natural Products: the Current Situation and Future Prospects , 2009, Marine drugs.

[31]  D. Bourdette,et al.  Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. , 2009, Prostaglandins, Leukotrienes and Essential Fatty Acids.

[32]  Y. Suh,et al.  Minocycline and neurodegenerative diseases , 2009, Behavioural Brain Research.

[33]  J. Litzman,et al.  Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis , 2009, Multiple sclerosis.

[34]  F. Munschauer,et al.  Quercetin and interferon-β modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients , 2008, Journal of Neuroimmunology.

[35]  J. Antel,et al.  Central nervous system-directed effects of FTY720 (fingolimod) , 2008, Journal of the Neurological Sciences.

[36]  H. Nagase,et al.  Progress in matrix metalloproteinase research. , 2008, Molecular aspects of medicine.

[37]  M. Trojano,et al.  Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients , 2008, Journal of Neuroimmunology.

[38]  A. Michael-Titus,et al.  Neurological Benefits of Omega-3 Fatty Acids , 2008, NeuroMolecular Medicine.

[39]  Y. Wan,et al.  Nuclear Receptors and Inflammatory Diseases , 2008, Experimental biology and medicine.

[40]  C. Wolfson,et al.  Environmental risk factors in multiple sclerosis , 2008, Acta neurologica Scandinavica. Supplementum.

[41]  A. Minagar,et al.  Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. , 2008, Archives of neurology.

[42]  C. Brinckerhoff,et al.  Signal transduction and cell‐type specific regulation of matrix metalloproteinase gene expression: Can MMPs be good for you? , 2007, Journal of cellular physiology.

[43]  R. D. Dyer,et al.  Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects* , 2007, Journal of Biological Chemistry.

[44]  Roland Martin,et al.  Multiple sclerosis: a complicated picture of autoimmunity , 2007, Nature Immunology.

[45]  T. Latronico,et al.  Inhibitory Effect of Polyunsaturated Fatty Acids on MMP-9 Release from Microglial Cells—Implications for Complementary Multiple Sclerosis Treatment , 2007, Neurochemical Research.

[46]  Jialiang Hu,et al.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.

[47]  M. Bähr,et al.  Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation , 2007, Neurobiology of Disease.

[48]  J. R. Mitchell,et al.  The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study , 2007, Multiple sclerosis.

[49]  P. E. Van den Steen,et al.  A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. , 2007, Biochimica et biophysica acta.

[50]  H. Hartung,et al.  Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. , 2006, Archives of neurology.

[51]  M. Bernardo,et al.  Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism‐based selective gelatinase inhibitor , 2006, International journal of cancer.

[52]  M. Esiri,et al.  Protein co-expression with axonal injury in multiple sclerosis plaques , 2006, Acta Neuropathologica.

[53]  C. Boz,et al.  Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing–remitting multiple sclerosis treated with interferon beta , 2006, Clinical Neurology and Neurosurgery.

[54]  V. Yong,et al.  Metalloproteinases: Mediators of Pathology and Regeneration in the CNS , 2005, Nature Reviews Neuroscience.

[55]  V. Yong,et al.  Effective combination of minocycline and interferon-β in a model of multiple sclerosis , 2005, Journal of Neuroimmunology.

[56]  M Ruggieri,et al.  Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment , 2005, Multiple sclerosis.

[57]  R. Ala-aho,et al.  Matrix metalloproteinases as therapeutic targets in cancer. , 2005, Current cancer drug targets.

[58]  W. Woodward,et al.  Lipoic acid in multiple sclerosis: a pilot study , 2005, Multiple sclerosis.

[59]  Yan Zhao,et al.  Eicosapentaenoic acid prevents lipopolysaccharide-stimulated DNA binding of activator protein-1 and c-Jun N-terminal kinase activity. , 2005, The Journal of nutritional biochemistry.

[60]  A. Bar-Or,et al.  Additive effect of the combination of glatiramer acetate and minocycline in a model of MS , 2005, Journal of Neuroimmunology.

[61]  B. Trapp.  Pathogenesis of multiple sclerosis: The eyes only see what the mind is prepared to comprehend , 2004, Annals of neurology.

[62]  E. Goetzl,et al.  The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  M. Duddy,et al.  Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. , 2003, Brain : a journal of neurology.

[64]  Helga E. de Vries,et al.  Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions , 2003, Journal of Neuroimmunology.

[65]  M. Trojano,et al.  Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes , 2003, Journal of Neuroimmunology.

[66]  A. Simopoulos.  Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases , 2002, Journal of the American College of Nutrition.

[67]  G. Rosenberg.  Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[68]  D. Bourdette,et al.  Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[69]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[70]  Susan Biggin,et al.  Inhibition of matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion drug design. , 2002, Biochemical pharmacology.

[71]  M. Trojano,et al.  Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis , 2002, Multiple sclerosis.

[72]  V. Yong,et al.  Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. , 2002, Brain : a journal of neurology.

[73]  I. Duncan,et al.  Inhibition of autoimmune encephalomyelitis by a tetracycline , 2002, Annals of neurology.

[74]  L. Kappos,et al.  The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. , 2001, Brain : a journal of neurology.

[75]  V. Giedraitis,et al.  Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. , 2001, Journal of autoimmunity.

[76]  K. Brew,et al.  Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.

[77]  M. Trojano,et al.  Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. , 1999, Neurology.

[78]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[79]  P. Slocombe,et al.  TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3 , 1998 .

[80]  K. Wucherpfennig,et al.  Effective treatment of models of multiple sclerosis with matrix metalloproteinase inhibitors , 1998, Journal of Neuroimmunology.

[81]  J. Cossins,et al.  Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions , 1997, Acta Neuropathologica.

[82]  J. Cossins,et al.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor , 1997, Journal of Neuroimmunology.

[83]  S. Chandler,et al.  Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview , 1997, Journal of Neuroimmunology.

[84]  E. Waubant,et al.  Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis , 1996, Annals of neurology.

[85]  J. Newcombe,et al.  The Expression of Tissue‐type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis: Comparison of Stages in Lesion Evolution , 1996, Journal of neuropathology and experimental neurology.

[86]  J. Uhm,et al.  Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9 , 1996 .

[87]  E. Roets,et al.  The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. , 1996, Biochemical pharmacology.

[88]  C. Ford,et al.  Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis , 1996, Neurology.

[89]  R. Sobel,et al.  Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions , 1996, Journal of neuropathology and experimental neurology.

[90]  S. Chandler,et al.  Matrix metalloproteinases degrade myelin basic protein , 1995, Neuroscience Letters.

[91]  J. Leonard,et al.  Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790 , 1995, Inflammation Research.

[92]  E. Waubant,et al.  T cell gelatinases mediate basement membrane transmigration in vitro. , 1995, Journal of immunology.

[93]  L. Steinman,et al.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. , 1994, The Journal of clinical investigation.

[94]  A. H. Drummond,et al.  Processing of tumour necrosis factor-α precursor by metalloproteinases , 1994, Nature.

[95]  G. Opdenakker,et al.  Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.

[96]  G. Opdenakker,et al.  Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders , 1992, Journal of Neuroimmunology.

[97]  Stephan Gebel,et al.  Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone , 1990, Cell.

[98]  D. Arnold,et al.  Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study , 2015 .

[99]  W. Baumgärtner,et al.  Matrix Metalloproteinases and Their Tissue Inhibitors in Cuprizone-Induced Demyelination and Remyelination of Brain White and Gray Matter , 2011, Journal of neuropathology and experimental neurology.

[100]  Seth M Cohen,et al.  To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. , 2010, Biochimica et biophysica acta.

[101]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[102]  R. Visse,et al.  Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry , 2003, Circulation research.